Celgene seeks court pronunciamento once again claims of romidepsin injection routine for the duration of T-cell lymphomas
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical guests developing voiced therapies that goal the many phases of room pattern pilot into the treatment of cancer and other grave disorders, today announced that it received a grievance filed not later than Celgene Corporation seeking a assertion from the court that four Cyclacel-owned patents, which put the handle of romidepsin injection in T-cell lymphomas, are not infringed in the main Celgene’s products and are imperfect. Cyclacel and its barrister deceive not had an whirl to definitely survey these filings.
The four patents cited in the grievance do not embrace Cyclacel’s clinical maturity candidates nor its commercial products.
INFORMANT Cyclacel Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
